• Entity registrant name: AETERNA ZENTARIS INC. (CIK: 0001113423)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1113423/000162828018003635/0001628280-18-003635-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1113423/000162828018003635/aezs-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • XBRL Cloud Rendering (requires license): Click to open XBRL Cloud Component Rendering
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001113423
  • Open this page in separate window: Click

    • * * *

    Component: (Network and Table)
    Network
    1003000 - Statement - Consolidated Statements of Comprehensive Loss
    (http://www.aezsinc.com/role/ConsolidatedStatementsOfComprehensiveLoss)
    Table (Implied)
    Slicers (applies to each fact value in each table cell)
    Reporting Entity [Axis] 0001113423 (http://www.sec.gov/CIK)
    Profit or loss [abstract] Period [Axis]
    2017-01-01 - 2017-12-31
    2016-01-01 - 2016-12-31
    2015-01-01 - 2015-12-31
    Profit or loss [abstract]
     
     
     
    Revenues
     
     
     
    Sales commission and other
    465,000  
    414,000  
    297,000  
    License fees (note 5)
    458,000  
    497,000  
    248,000  
    Total revenues
    923,000  
     
    911,000  
     
    545,000  
     
    Operating expenses (note 17)
     
     
     
    Research and development costs
    10,704,000  
    16,495,000  
    17,234,000  
    General and administrative expenses
    8,198,000  
    7,147,000  
    11,308,000  
    Selling expenses
    5,095,000  
    6,745,000  
    6,887,000  
    Total operating expenses
    23,997,000  
     
    30,387,000  
     
    35,429,000  
     
    Loss from operations
    (23,074,000) 
     
    (29,476,000) 
     
    (34,884,000) 
     
    Gain (loss) due to changes in foreign currency exchange rates
    502,000  
    (70,000) 
    (1,767,000) 
    Change in fair value of warrant liability (note 14)
    2,222,000  
    4,437,000  
    (10,956,000) 
    Warrant exercise inducement fee (note 14)
    0  
    0  
    (2,926,000) 
    Other finance income
    75,000  
    150,000  
    305,000  
    Net finance income (costs)
    2,799,000  
     
    4,517,000  
     
    (15,344,000) 
     
    Loss before income taxes
    (20,275,000) 
     
    (24,959,000) 
     
    (50,228,000) 
     
    Income tax recovery (note 20)
    3,479,000  
    0  
    0  
    Net loss from continuing operations
    (16,796,000) 
     
    (24,959,000) 
     
    (50,228,000) 
     
    Net income from discontinued operations
    0  
    0  
    85,000  
    Net loss
    (16,796,000) 
     
    (24,959,000) 
     
    (50,143,000) 
     
    Other comprehensive income (loss):
     
     
     
    Items that may be reclassified subsequently to profit or loss:
     
     
     
    Foreign currency translation adjustments
    (1,430,000) 
    569,000  
    1,509,000  
    Items that will not be reclassified to profit or loss:
     
     
     
    Actuarial gain (loss) on defined benefit plans (note 18)
    694,000  
    (1,479,000) 
    844,000  
    Comprehensive loss
    (17,532,000) 
    (25,869,000) 
    (47,790,000) 
    Net loss per share (basic and diluted) from continuing operations (in dollars per share)
    (1.12)1
    (2,410.00)1
    (18,170.00)1
    Net income per share (basic and diluted) from discontinued operations (in dollars per share)
    .00 1
    .00 1
    30.00 1
    Net loss per share (basic and diluted) (in dollars per share)
    (1.12)1
     
    (2,410.00)1
     
    (18,140.00)1
     
    Weighted average number of shares outstanding (notes 24):
     
     
     
    Basic and diluted (in shares)
    14,958,704  
    10,348,879  
    2,763,603  
    Stock split, conversion ratio
    100  
    		    
    1: Adjusted to reflect the November 17, 2015 100-to-1 Share Consolidation (see note 1 - Business overview and note 16 - Share capital).